



IPC-3D

An R&D platform at the leading edge of leukaemia treatment

Within Carnot OPALE institute, the IPC-Drug Discovery and Development programme (IPC-3D) offers a unique platform catering to the needs of players in the biopharmaceutical sector. IPC-3D is focused exclusively on the key issues involved in their pipeline development, from identification of new therapeutic targets through early evaluation of drug candidates in humans.

Carnot OPALE Institute

Scientific / technological breakthrough

The scientific and technological breakthrough covers:

- the discovery of a new class of therapeutic antibodies in preclinical Acute myeloid leukaemia models (AML) and in other tumour models, leading to the creation of ImCheck Therapeutics by researchers from the Marseilles Cancer Research Centre (CRCM) and Institut Paoli Calmettes (IPC), both part of Carnot OPALE Institute,
- initiation of early-stage trials (notably in AML), highlighting the potential of the IPC-3D programme and the opportunity for its large-scale development in partnership with Carnot OPALE Institute.



Competitive advantage for the economic stakeholders

IPC-3D provides an integrated range of resources including:

- a cohort of leukaemia patients,
- collections of biological samples complete with clinical and biological data,
- ad hoc experimental models (annotated PDX xenobank),
- basic, translational and clinical research expertise, and technologies organised around leukaemia treatment,
- accredited infrastructures and partner networks,
- tried and tested experience in industrial partnerships.

It rounds out the offering of pharmaceutical companies in developing drug candidates.

Partnership

- ImCheck Therapeutics designs and develops new-generation immunotherapy antibodies capable of modulating innate and adaptive immunity simultaneously.

These antibodies may be complementary – or even better than – first-generation checkpoint inhibitors in cancer, and may potentially be developed in auto-immune and infectious diseases.



Contact

Carnot OPALE Institute - Thomas IVANOFF - thomas.ivanoff@opale.org Imcheck Therapeutics - Pierre DEPENOUX - pierre.depenoux@imcheck.fr